Proposed changes to ABPI Code of practice could hurt smaller firms, warns EMIG - update
This article was originally published in Scrip
Proposed changes to the ABPI (Association of the British Pharmaceutical Industry) code of practice, now out for consultation, could help improve transparency in the pharmaceutical industry. But plans to limit branded giveaways to healthcare professionals could disproportionately hurt smaller firms, making the code "unfit for purpose", warns the Ethical Medicines Industry Group, EMIG.
You may also be interested in...
Developing biosimilar orphan drugs is fraught with challenges and needs buy-in from regulators, developers, patients and clinicians.
In addition to agreeing to emergency use of the Oxford University/Astra Zeneca and Sinovac vaccines, Brazil's medicines regulator has also published good manufacturing practices certificates for Pfizer and Janssen vaccine. It has questions about the Sputnik V authorization request.
A Dutch parallel registration and reimbursement pilot has brought benefits including more participation from healthcare professionals, and also forces company divisions to be less streamlined.